New partnership to develop schizophrenia treatments New partnership to develop schizophrenia treatments Boehringer Ingelheim partners with Sosei Heptares to develop next generation schizophrenia treatments
Cystic Fibrosis Genetherapy Development Option Excercise Cystic Fibrosis Genetherapy Development Option Excercise Boehringer Ingelheim and Partners Accelerate BI 3720931 Gene Therapy as long-lasting therapeutic option for patients with cystic fibrosis
real-world-benefit-shown-in-T2D-treatment real-world-benefit-shown-in-T2D-treatment Real-world evidence study shows type 2 diabetes treatment reduced risk of cardiovascular events and hospitalization for heart failure
emperor-preserved-chmp-positive-opinion emperor-preserved-chmp-positive-opinion CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
reduced-heart-failure-treatment-approval-europe reduced-heart-failure-treatment-approval-europe European approval for treatment of adults with heart failure with reduced ejection fraction
DCRI-collaboration-empact-mi DCRI-collaboration-empact-mi Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction
emperor-reduced-chmp-positive-opinion emperor-reduced-chmp-positive-opinion CHMP issues positive opinion for the treatment of adults with heart failure with reduced ejection fraction
emperor-preserved-heart-failure-toplineresults emperor-preserved-heart-failure-toplineresults Positive, top-line results announced from the EMPEROR-Preserved Phase III trial in adults with heart failure with preserved ejection fraction
preserved-heart-failure-treatment-approval-europe preserved-heart-failure-treatment-approval-europe preserved-heart-failure-treatment-approval-europe
preserved-heart-failure-treatment-FDA-US-approval preserved-heart-failure-treatment-FDA-US-approval US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
empulse-trial-benefit-acute-heart-failure empulse-trial-benefit-acute-heart-failure Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
emperor-reduced-heart-failure-toplineresults emperor-reduced-heart-failure-toplineresults Positive, top-line results announced from the EMPEROR-Reduced Phase III trial in adults with chronic heart failure with reduced ejection fraction
EMPA-KIDNEY trial early stop due to positive efficacy EMPA-KIDNEY trial early stop due to positive efficacy EMPA-KIDNEY, the largest SGLT2 inhibitor trial in chronic kidney disease, will stop early due to clear evidence of positive efficacy
emperor-preserved-kidney-subanalysis emperor-preserved-kidney-subanalysis New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status
Bringing focus to biliary tract and pancreatic cancers Bringing focus to biliary tract and pancreatic cancers The Brightline-2 clinical trial is studying our investigational MDM2-p53 antagonist for people with advanced biliary tract and pancreatic cancers.